#South Korea #Daejeon #ADC therapy #Alteogen #ALT-B4

Introduction

At the World ADC Summit 2026 held in South Korea, Alteogen Inc. presented groundbreaking preclinical findings showcasing the potential of their proprietary enzyme, ALT-B4 (berahyaluronidase alfa), to advance antibody-drug conjugate (ADC) therapy. Their research highlights significant improvements in pharmacokinetic (PK) parameters, safety profile, and the overall therapeutic landscape for ADC applications. This article delves deeper into the specifics of the study findings and their implications for future developments in ADC treatments.

Key Findings from the Preclinical Study

The study conducted by Alteogen has provided promising insights, particularly in the context of subcutaneous (SC) administration of ADCs using ALT-B4. The research encompassed tests on Alteogen's proprietary ADC, ALT-P7 (anti-HER2 ADC), in minipigs, wherein various administration methods were compared. Here are the main results:

1. Enhanced Pharmacokinetics: The administration of ADCs combined with ALT-B4 showcased rapid absorption rates. It resulted in improved systemic exposure and bioavailability compared to SC administration without ALT-B4. This finding indicates that integrating ALT-B4 into ADC therapies can significantly enhance their delivery and uptake in the body.

2. Reduced Local Toxicity: One of the standout outcomes was a notable decrease in local dermal toxicity at the injection site for the ALT-B4 combination SC group. The preclinical model revealed a clear, dose-dependent decline in skin reactions, a critical factor in patient tolerance and comfort during treatment.

3. Improved Hematologic Safety: Hematologic safety parameters, including absolute neutrophil count (ANC) and levels of triglycerides and aspartate aminotransferase (AST), were also compared across different administration methods. Unlike intravenous (IV) infusion, which showed significant drops in neutrophil counts coupled with elevated triglycerides and AST, the ALT-B4 group maintained a more stable hematologic profile, indicating a favorable safety margin.

Implications for ADC Therapy Development

These findings from Alteogen have significant ramifications. Firstly, enhancing the delivery method of ADCs can lead to more effective treatments with fewer side effects. The improved safety profile resulting from reduced local toxicity and better management of hematologic parameters can ultimately lead to higher patient compliance and better overall treatment outcomes.

Tae-Yon Chun, Ph.D., the CEO of Alteogen, expressed optimism regarding the study results, stating: "Combining ALT-B4 reduces injection-site skin reactions and offers improvements in PK parameters. These findings suggest that ALT-B4-enabled formulations can catalyze a paradigm shift in optimizing both the PK and safety profiles of ADC therapies. We foresee this innovation facilitating strategic partnerships in the ADC landscape."

Conclusion

In summary, Alteogen's presentations at World ADC Summit 2026 could mark a turning point in the ADC landscape. With ongoing advancements in drug delivery systems, the implications of ALT-B4 extend beyond mere drug administration improvements; they could redefine how ADC therapies are perceived and utilized in clinical settings. The card is now in the hands of industry stakeholders to explore the full potential of ALT-B4 and its role in transforming ADC therapy into a more patient-friendly, effective modality.

As the biopharmaceutical sector continues to evolve, Alteogen’s contributions will undoubtedly be pivotal in driving forward the future of ADC technologies.